Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15023709 | 0.93 | GRM5 (0.49) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034523 | 0.92 | GRM5 (0.53) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034530 | 0.92 | L3MBTL1 (0.52) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034553 | 0.92 | L3MBTL1 (0.52) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034549 | 0.91 | GRM5 (0.47) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034521 | 0.90 | GRM5 (0.48) | L3MBTL1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15034557 | 0.90 | POLB (0.46) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034511 | 0.87 | SLC6A7 (0.54) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034522 | 0.87 | GRM5 (0.50) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A | |
| SCHEMBL15034551 | 0.86 | GRM5 (0.51) | L3MBTL1MAPTMAPK1ALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937176-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
| US-20130158038-A1 | NOVEL COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158038-A1 | NOVEL COMPOUNDS | GRM5, GRIN1, GRM1 | L3MBTL1 3435/4885MAPT 281/4885MAPK1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.